Skip to main content

Priyanka Grover

Analyst

J.P. Morgan

Equibles does not estimate personal net worth.

About Priyanka Grover

Priyanka Grover is recorded as Analyst at J.P. Morgan. Priyanka Grover has spoken on 4 earnings calls and 1 other investor event across 3 companies, most recently for Kura Oncology, Inc. on November 10, 2026. Those appearances were for Kura Oncology, Inc. (KURA), Rhythm Pharmaceuticals, Inc. (RYTM) and Nuvation Bio Inc. (NUVB). The companies whose calls Priyanka Grover spoke on are classified in the Healthcare sector.

Priyanka Grover on recent calls

“Troy, congratulations from all of us at JPMorgan, especially the entire biotech team. We just have one question. Nearly half received ComZifty in combination with other approved agents.”
Analyst — JPMorgan, Kura Oncology, Inc. Q3 FY2026 Earnings Call ·
“So, on the persistent trends on the front line and second line, what have you seen throughout the quarter? Basically, are discontinuation rates still tracking with what was shown in the clinical trials?”
Analyst — J.P. Morgan, Third Quarter 2026 Financial Results and Business Update ·
“So, one thing you mentioned in the beginning of the call is Japan may be the second largest market for you guys. Considering EU has an estimated 10,000 patients for acquired HO, can you provide more color on the major confidence in the Japanese market?”
Analyst — J.P. Morgan, Rhythm Pharmaceuticals Q3 2026 Earnings Conference Call ·
“How do you think about KO7246 in positioning it in the diabetes treatment landscape especially with the possible combination used with GLP-1s.”
Analyst — JP Morgan, Kura Oncology EASD Virtual Investor Event ·
“Thanks so much for taking our question and congrats on the quarter so we just have a question about europe aside from the one time revenue recognition charge in france were there any other factors to think about for europe in the past quarters europe has been a strong growth driver for rhythm so curious how are you…”
Analyst — J.P. Morgan, Rhythm Pharmaceuticals Q2 2026 Earnings Conference Call ·

Affiliation history

  • J.P. Morgan

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity